BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lymphoma AND ALK, CD246, ENSG00000171094, 238, Q9UM73, TFG/ALK AND Prognosis
634 results:

  • 1. Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review.
    Khasraw M; Yalamanchili P; Santhanagopal A; Wu C; Salas M; Meng J; Karnoub M; Esker S; Felip E
    Adv Ther; 2024 May; 41(5):1815-1842. PubMed ID: 38509433
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory alk+ ALCL.
    Liu W; Wu J; Ming X; Zhang Q; Zhou D; Zheng R; Zhou M; Shang Z; Chen L; Zhu X; Xiao Y
    Front Immunol; 2024; 15():1346001. PubMed ID: 38375471
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Longitudinal plasma proteomic profiling of EML4-alk positive lung cancer receiving alk-TKIs therapy.
    Wang S; Hao X; Dai L; Lou N; Fan G; Gao R; Yang M; Xing P; Liu Y; Wang L; Zhang Z; Yao J; Tang L; Shi Y; Han X
    Lung Cancer; 2024 Mar; 189():107503. PubMed ID: 38359741
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. 2021 WHO Classification of Lung Cancer: Molecular Biology Research and Radiologic-Pathologic Correlation.
    Sasaki T; Kuno H; Hiyama T; Oda S; Masuoka S; Miyasaka Y; Taki T; Nagasaki Y; Ohtani-Kim SJ; Ishii G; Kaku S; Shroff GS; Kobayashi T
    Radiographics; 2024 Mar; 44(3):e230136. PubMed ID: 38358935
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Targeting alk averts ribonuclease 1-induced immunosuppression and enhances antitumor immunity in hepatocellular carcinoma.
    Liu C; Zhou C; Xia W; Zhou Y; Qiu Y; Weng J; Zhou Q; Chen W; Wang YN; Lee HH; Wang SC; Kuang M; Yu D; Ren N; Hung MC
    Nat Commun; 2024 Feb; 15(1):1009. PubMed ID: 38307859
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Aggressive T-cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management.
    Ong SY; Zain JM
    Am J Hematol; 2024 Mar; 99(3):439-456. PubMed ID: 38304959
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Prognostic factors for invasive mucinous adenocarcinoma of the lung: systematic review and meta-analysis.
    Zhao T; Yi J; Luo D; Liu J; Fan X; Wu Q; Wang W
    World J Surg Oncol; 2024 Feb; 22(1):41. PubMed ID: 38303008
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Gastric and cardiac inflammatory myofibroblastic tumor: an extremely rare case.
    Huang Y; Zhang M; Li Q; Huang Q
    J Cardiothorac Surg; 2024 Jan; 19(1):31. PubMed ID: 38287440
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Evaluation of Immunohistochemical Expression of alk-1 in Gliomas, WHO Grade 4 and Its Correlation with IDH1-R132H Mutation Status.
    Khairy RA; Momtaz EM; Abd El Aziz AM; Shibel PEE
    Asian Pac J Cancer Prev; 2024 Jan; 25(1):317-323. PubMed ID: 38285799
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Lung adenocarcinoma with brain metastasis detected dual fusion of LOC399815-alk and alk-EML4 in combined treatment of Alectinib and CyberKnife: A case report.
    Li Y; Lu S; Yao P; Huang W; Huang Y; Zhou Y; Yuan Y; Cheng S; Wu F
    Medicine (Baltimore); 2024 Jan; 103(3):e36992. PubMed ID: 38241569
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Successful application of lorlatinib in a 23-year-old patient with anaplastic lymphoma kinase (alk)-positive lung cancer and multiple brain metastases.
    Murakami Y; Kawashima Y; Chiba S; Hara S; Yamazaki Y; Doman T; Saito S; Odaka T; Ogasawara T; Shimizu H; Sugisaka J; Aiba T; Toi Y; Yamanda S; Kimura Y; Sugawara S
    Cancer Rep (Hoboken); 2024 Feb; 7(2):e1981. PubMed ID: 38212894
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. A rare case of fluid overload-associated large B-cell lymphoma and antigen loss at relapse.
    Yan X; Chen B; Jing H; Yang Z; Zhang T; Lin Y; Shi J
    J Hematop; 2023 Dec; 16(4):235-240. PubMed ID: 38175437
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Abdominal inflammatory myofibroblastic tumour: Clinicopathological and molecular analysis of 20 cases, highlighting potential therapeutic targets.
    Vernemmen AIP; Samarska IV; Speel EM; Riedl RG; Goudkade D; de Bruïne AP; Wouda S; van Marion AM; Verlinden IV; van Lijnschoten I; Friederich P; Winnepenninckx VJL; Zur Hausen A; Sciot RME; van den Hout MFCM
    Histopathology; 2024 Apr; 84(5):794-809. PubMed ID: 38155480
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Case report: Differential diagnosis of highly amplified anti-CD5 CAR T cells and relapsed lymphoma cells in a patient with refractory alk positive anaplastic large cell lymphoma.
    Mu W; Zhang M; Hu G; Han Y; Mao X; Chen C; Shen K; Dai Z; Zhu X; Zhou X; Huang L; Ao Q; Xiao M
    Front Immunol; 2023; 14():1280007. PubMed ID: 38143760
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Validation of the alk-Brain Prognostic Index for patients with alk-rearranged lung cancer and brain metastases.
    Zerdes I; Kamali C; Koulouris A; Elsayed M; Schnorbach J; Christopoulos P; Tsakonas G
    ESMO Open; 2023 Dec; 8(6):102069. PubMed ID: 37988952
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. [Analysis of Clinicopathological Features on Spread Through Air Spaces
of Lung Adenocarcinoma].
    Fan L; Qin J; Lin X; Wu Y; He Z; He P
    Zhongguo Fei Ai Za Zhi; 2023 Sep; 26(9):650-658. PubMed ID: 37985151
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Transformation of NSCLC to SCLC harboring EML4-alk fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.
    Lingling X; Maoxi C; Wei Y; Jieting Z; Yuanyuan Y; Ning X
    Lung Cancer; 2023 Dec; 186():107415. PubMed ID: 37907052
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Acquired resistance to crizotinib in novel CDK14-alk and CLTC-alk fusions of alk-positive large B-cell lymphoma identified by next-generation sequencing.
    Xia Y; Zhang L; He W; Pan H; Fang J; Cui G
    Cancer Biol Ther; 2023 Dec; 24(1):2271212. PubMed ID: 37906510
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, alk and ROS1 tyrosine kinase inhibitors: An update.
    Moes-Sosnowska J; Szpechcinski A; Chorostowska-Wynimko J
    Tumour Biol; 2024; 46(s1):S309-S325. PubMed ID: 37840519
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Leukaemic Presentation of Small-Cell alk-Positive Anaplastic Large Cell lymphoma in a Young Woman-Report of a Case with 9-Year Survival.
    Santonja C; Morillo-Giles D; Prieto-Pareja E; Soto-de Ozaeta C; Serrano-Del Castillo C; Salgado-Sánchez R; Yi-Shi AW; Manso R; Rodríguez-Pinilla SM
    Medicina (Kaunas); 2023 Sep; 59(9):. PubMed ID: 37763746
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 32.